JP2015505542A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505542A5 JP2015505542A5 JP2014553655A JP2014553655A JP2015505542A5 JP 2015505542 A5 JP2015505542 A5 JP 2015505542A5 JP 2014553655 A JP2014553655 A JP 2014553655A JP 2014553655 A JP2014553655 A JP 2014553655A JP 2015505542 A5 JP2015505542 A5 JP 2015505542A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyrazin
- ethyl
- amino
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 230000001419 dependent effect Effects 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 210000003734 kidney Anatomy 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000002615 epidermis Anatomy 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000000066 myeloid cell Anatomy 0.000 claims 2
- OKPBZUTXNVCBHM-UHFFFAOYSA-N n-methyl-n-[2-[methyl-[6-[4-[6-(methylaminomethyl)pyridin-3-yl]phenoxy]pyrazin-2-yl]amino]ethyl]acetamide Chemical compound C1=NC(CNC)=CC=C1C(C=C1)=CC=C1OC1=CN=CC(N(C)CCN(C)C(C)=O)=N1 OKPBZUTXNVCBHM-UHFFFAOYSA-N 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- -1 tert-butyloxy, neopentyl Chemical group 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 210000004291 uterus Anatomy 0.000 claims 2
- IAYIVOHVDGNJAW-UHFFFAOYSA-N 1-[2-[[6-[4-(5-methylpyridin-2-yl)phenoxy]pyrazin-2-yl]amino]ethyl]piperidin-2-one Chemical compound N1=CC(C)=CC=C1C(C=C1)=CC=C1OC1=CN=CC(NCCN2C(CCCC2)=O)=N1 IAYIVOHVDGNJAW-UHFFFAOYSA-N 0.000 claims 1
- MSDPXGZYQDMCRP-UHFFFAOYSA-N 1-[2-[methyl-[6-[4-(5-methylpyridin-2-yl)phenoxy]pyrazin-2-yl]amino]ethyl]piperidin-2-one Chemical compound C=1N=CC(OC=2C=CC(=CC=2)C=2N=CC(C)=CC=2)=NC=1N(C)CCN1CCCCC1=O MSDPXGZYQDMCRP-UHFFFAOYSA-N 0.000 claims 1
- YBJHBAHKTGYVGT-UHFFFAOYSA-N 5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanoic acid Chemical compound N1C(=O)NC2C(CCCCC(=O)O)SCC21 YBJHBAHKTGYVGT-UHFFFAOYSA-N 0.000 claims 1
- CMUGHZFPFWNUQT-HUBLWGQQSA-N 6-[5-(2-oxo-hexahydro-thieno[3,4-d]imidazol-4-yl)-pentanoylamino]-hexanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)O)SC[C@@H]21 CMUGHZFPFWNUQT-HUBLWGQQSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- UMWYPMUNNQMKCC-UHFFFAOYSA-N CN(CCN(C)c1cncc(Oc2ccc(cc2)-c2ccc(cn2)[N+]([O-])=O)n1)C(C)=O Chemical compound CN(CCN(C)c1cncc(Oc2ccc(cc2)-c2ccc(cn2)[N+]([O-])=O)n1)C(C)=O UMWYPMUNNQMKCC-UHFFFAOYSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- BKIOIASWRZYNMC-UHFFFAOYSA-N N-[2-[[6-[4-[6-[4-(6-aminohexanoyl)piperazin-1-yl]pyridin-3-yl]phenoxy]pyrazin-2-yl]-methylamino]ethyl]-N-methylacetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2C=NC(=CC=2)N2CCN(CC2)C(=O)CCCCCN)=N1 BKIOIASWRZYNMC-UHFFFAOYSA-N 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- SXECCXUBNRDIRK-UHFFFAOYSA-N n-[2-[6-[4-(5-methylpyridin-2-yl)phenoxy]pyrazin-2-yl]sulfanylethyl]-n-propan-2-ylacetamide Chemical compound CC(C)N(C(C)=O)CCSC1=CN=CC(OC=2C=CC(=CC=2)C=2N=CC(C)=CC=2)=N1 SXECCXUBNRDIRK-UHFFFAOYSA-N 0.000 claims 1
- ZCSUOEYWGSYHDE-UHFFFAOYSA-N n-[2-[[6-[2-fluoro-4-(5-fluoropyridin-2-yl)phenoxy]pyrazin-2-yl]-methylamino]ethyl]-n-methylacetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C(=CC(=CC=2)C=2N=CC(F)=CC=2)F)=N1 ZCSUOEYWGSYHDE-UHFFFAOYSA-N 0.000 claims 1
- AMOYNRBZVPREEJ-UHFFFAOYSA-N n-[2-[[6-[2-fluoro-4-(5-methylpyridin-2-yl)phenoxy]pyrazin-2-yl]-methylamino]ethyl]-n-methylacetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C(=CC(=CC=2)C=2N=CC(C)=CC=2)F)=N1 AMOYNRBZVPREEJ-UHFFFAOYSA-N 0.000 claims 1
- NMEYBBIHHOAULH-UHFFFAOYSA-N n-[2-[[6-[2-fluoro-4-(6-morpholin-4-ylpyridin-3-yl)phenoxy]pyrazin-2-yl]-methylamino]ethyl]-n-methylacetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C(=CC(=CC=2)C=2C=NC(=CC=2)N2CCOCC2)F)=N1 NMEYBBIHHOAULH-UHFFFAOYSA-N 0.000 claims 1
- LNXXFRZZOMSYFT-UHFFFAOYSA-N n-[2-[[6-[4-(2-aminopyrimidin-4-yl)phenoxy]pyrazin-2-yl]-methylamino]ethyl]-n-methylacetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2N=C(N)N=CC=2)=N1 LNXXFRZZOMSYFT-UHFFFAOYSA-N 0.000 claims 1
- BXRDLTFAIAKKNX-UHFFFAOYSA-N n-[2-[[6-[4-(2-cyanopyridin-4-yl)phenoxy]pyrazin-2-yl]-methylamino]ethyl]-n-methylacetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2C=C(N=CC=2)C#N)=N1 BXRDLTFAIAKKNX-UHFFFAOYSA-N 0.000 claims 1
- BPACBFXULSQLDW-UHFFFAOYSA-N n-[2-[[6-[4-(2-fluoropyridin-4-yl)phenoxy]pyrazin-2-yl]-methylamino]ethyl]-n-methylacetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2C=C(F)N=CC=2)=N1 BPACBFXULSQLDW-UHFFFAOYSA-N 0.000 claims 1
- CRUUFNUBDCUODT-UHFFFAOYSA-N n-[2-[[6-[4-(3-cyanopyridin-4-yl)-2-fluorophenoxy]pyrazin-2-yl]-methylamino]ethyl]-n-methylacetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C(=CC(=CC=2)C=2C(=CN=CC=2)C#N)F)=N1 CRUUFNUBDCUODT-UHFFFAOYSA-N 0.000 claims 1
- LPDPCXPKZWNOGE-UHFFFAOYSA-N n-[2-[[6-[4-(3-cyanopyridin-4-yl)phenoxy]pyrazin-2-yl]-methylamino]ethyl]-n-methylacetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2C(=CN=CC=2)C#N)=N1 LPDPCXPKZWNOGE-UHFFFAOYSA-N 0.000 claims 1
- LCAZWQCKEMBHKH-UHFFFAOYSA-N n-[2-[[6-[4-(5-aminopyrazin-2-yl)phenoxy]pyrazin-2-yl]-methylamino]ethyl]-n-methylacetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2N=CC(N)=NC=2)=N1 LCAZWQCKEMBHKH-UHFFFAOYSA-N 0.000 claims 1
- IICGIVPNGIVPHS-UHFFFAOYSA-N n-[2-[[6-[4-(5-azidopyridin-2-yl)phenoxy]pyrazin-2-yl]-methylamino]ethyl]-n-methylacetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2N=CC(=CC=2)N=[N+]=[N-])=N1 IICGIVPNGIVPHS-UHFFFAOYSA-N 0.000 claims 1
- KWESHVKSKXFOQE-UHFFFAOYSA-N n-[2-[[6-[4-(5-fluoropyridin-2-yl)phenoxy]pyrazin-2-yl]-methylamino]ethyl]-n-methylacetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2N=CC(F)=CC=2)=N1 KWESHVKSKXFOQE-UHFFFAOYSA-N 0.000 claims 1
- GZKZWHKTSUWIJT-UHFFFAOYSA-N n-[2-[[6-[4-(5-methoxypyridin-2-yl)phenoxy]pyrazin-2-yl]-methylamino]ethyl]-n-methylacetamide Chemical compound N1=CC(OC)=CC=C1C(C=C1)=CC=C1OC1=CN=CC(N(C)CCN(C)C(C)=O)=N1 GZKZWHKTSUWIJT-UHFFFAOYSA-N 0.000 claims 1
- JMRDBWAMAQBISE-UHFFFAOYSA-N n-[2-[[6-[4-(6-aminopyridin-2-yl)phenoxy]pyrazin-2-yl]-methylamino]ethyl]-n-methylacetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2N=C(N)C=CC=2)=N1 JMRDBWAMAQBISE-UHFFFAOYSA-N 0.000 claims 1
- AKTIYLRDMGCPSO-UHFFFAOYSA-N n-[2-[[6-[4-(6-cyanopyridin-3-yl)phenoxy]pyrazin-2-yl]-methylamino]ethyl]-n-methylacetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2C=NC(=CC=2)C#N)=N1 AKTIYLRDMGCPSO-UHFFFAOYSA-N 0.000 claims 1
- JAJIIHLFYUFSIJ-UHFFFAOYSA-N n-[2-[[6-[4-[6-(hydroxymethyl)pyridin-3-yl]phenoxy]pyrazin-2-yl]-methylamino]ethyl]-n-methylacetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2C=NC(CO)=CC=2)=N1 JAJIIHLFYUFSIJ-UHFFFAOYSA-N 0.000 claims 1
- NNWDBFSGOYPWIT-UHFFFAOYSA-N n-[5-[4-[6-[2-[acetyl(methyl)amino]ethyl-methylamino]pyrazin-2-yl]oxy-3-fluorophenyl]pyridin-2-yl]acetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C(=CC(=CC=2)C=2C=NC(NC(C)=O)=CC=2)F)=N1 NNWDBFSGOYPWIT-UHFFFAOYSA-N 0.000 claims 1
- ZVIIYVVBSVBDOM-UHFFFAOYSA-N n-[5-[4-[6-[2-[acetyl(methyl)amino]ethyl-methylamino]pyrazin-2-yl]oxyphenyl]pyridin-2-yl]acetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2C=NC(NC(C)=O)=CC=2)=N1 ZVIIYVVBSVBDOM-UHFFFAOYSA-N 0.000 claims 1
- SQJXWBYHQXSQKE-UHFFFAOYSA-N n-[6-[4-[6-[2-[acetyl(methyl)amino]ethyl-methylamino]pyrazin-2-yl]oxyphenyl]pyridin-2-yl]acetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2N=C(NC(C)=O)C=CC=2)=N1 SQJXWBYHQXSQKE-UHFFFAOYSA-N 0.000 claims 1
- FXDUNTQJDBNYBM-UHFFFAOYSA-N n-ethyl-n-[2-[6-[4-(5-methylpyridin-2-yl)phenoxy]pyrazin-2-yl]sulfanylethyl]acetamide Chemical compound CCN(C(C)=O)CCSC1=CN=CC(OC=2C=CC(=CC=2)C=2N=CC(C)=CC=2)=N1 FXDUNTQJDBNYBM-UHFFFAOYSA-N 0.000 claims 1
- AHINMVOEKJEPPV-UHFFFAOYSA-N n-methyl-3-[methyl-[6-[4-(5-methylpyridin-2-yl)phenoxy]pyrazin-2-yl]amino]propanamide Chemical compound CNC(=O)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2N=CC(C)=CC=2)=N1 AHINMVOEKJEPPV-UHFFFAOYSA-N 0.000 claims 1
- CVKLBVGHLHNKHS-UHFFFAOYSA-N n-methyl-n-[2-[6-[4-(5-methylpyridin-2-yl)phenoxy]pyrazin-2-yl]sulfanylethyl]acetamide Chemical compound CC(=O)N(C)CCSC1=CN=CC(OC=2C=CC(=CC=2)C=2N=CC(C)=CC=2)=N1 CVKLBVGHLHNKHS-UHFFFAOYSA-N 0.000 claims 1
- ABXORIGECMXSTH-UHFFFAOYSA-N n-methyl-n-[2-[methyl-[6-(4-pyridin-2-ylphenoxy)pyrazin-2-yl]amino]ethyl]acetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2N=CC=CC=2)=N1 ABXORIGECMXSTH-UHFFFAOYSA-N 0.000 claims 1
- CLPPYFZJVJCQPD-UHFFFAOYSA-N n-methyl-n-[2-[methyl-[6-(4-pyridin-4-ylphenoxy)pyrazin-2-yl]amino]ethyl]acetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2C=CN=CC=2)=N1 CLPPYFZJVJCQPD-UHFFFAOYSA-N 0.000 claims 1
- AIIVJLWYWWZCQE-UHFFFAOYSA-N n-methyl-n-[2-[methyl-[6-[4-(1,3-thiazol-2-yl)phenoxy]pyrazin-2-yl]amino]ethyl]acetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2SC=CN=2)=N1 AIIVJLWYWWZCQE-UHFFFAOYSA-N 0.000 claims 1
- LUJRZYDSQWMMHV-UHFFFAOYSA-N n-methyl-n-[2-[methyl-[6-[4-(1h-pyrrolo[2,3-c]pyridin-5-yl)phenoxy]pyrazin-2-yl]amino]ethyl]acetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2N=CC=3NC=CC=3C=2)=N1 LUJRZYDSQWMMHV-UHFFFAOYSA-N 0.000 claims 1
- UZEUDQHJIWFBPX-UHFFFAOYSA-N n-methyl-n-[2-[methyl-[6-[4-(5-methylpyridin-2-yl)phenoxy]pyrazin-2-yl]amino]ethyl]acetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2N=CC(C)=CC=2)=N1 UZEUDQHJIWFBPX-UHFFFAOYSA-N 0.000 claims 1
- OQFALOXDLYJORL-UHFFFAOYSA-N n-methyl-n-[2-[methyl-[6-[4-(6-methylpyridin-2-yl)phenoxy]pyrazin-2-yl]amino]ethyl]acetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2N=C(C)C=CC=2)=N1 OQFALOXDLYJORL-UHFFFAOYSA-N 0.000 claims 1
- PIFVKHOMCACBMI-UHFFFAOYSA-N n-methyl-n-[2-[methyl-[6-[4-(6-methylpyridin-3-yl)phenoxy]pyrazin-2-yl]amino]ethyl]acetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2C=NC(C)=CC=2)=N1 PIFVKHOMCACBMI-UHFFFAOYSA-N 0.000 claims 1
- NYYHHCCHKYIWNC-UHFFFAOYSA-N n-methyl-n-[2-[methyl-[6-[4-(6-methylsulfonylpyridin-2-yl)phenoxy]pyrazin-2-yl]amino]ethyl]acetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2N=C(C=CC=2)S(C)(=O)=O)=N1 NYYHHCCHKYIWNC-UHFFFAOYSA-N 0.000 claims 1
- CMQWXGQEPJOJPC-UHFFFAOYSA-N n-methyl-n-[2-[methyl-[6-[4-(6-morpholin-4-ylpyridin-3-yl)phenoxy]pyrazin-2-yl]amino]ethyl]acetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2C=NC(=CC=2)N2CCOCC2)=N1 CMQWXGQEPJOJPC-UHFFFAOYSA-N 0.000 claims 1
- JMNKYIAQLNRPDF-UHFFFAOYSA-N n-methyl-n-[2-[methyl-[6-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenoxy]pyrazin-2-yl]amino]ethyl]acetamide Chemical compound CC(=O)N(C)CCN(C)C1=CN=CC(OC=2C=CC(=CC=2)C=2C=3C=CNC=3N=CN=2)=N1 JMNKYIAQLNRPDF-UHFFFAOYSA-N 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12000559.0 | 2012-01-28 | ||
| EP12000559 | 2012-01-28 | ||
| PCT/EP2013/000050 WO2013110433A1 (en) | 2012-01-28 | 2013-01-10 | Azaheterocyclic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015505542A JP2015505542A (ja) | 2015-02-23 |
| JP2015505542A5 true JP2015505542A5 (enExample) | 2016-03-03 |
Family
ID=47603585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553655A Ceased JP2015505542A (ja) | 2012-01-28 | 2013-01-10 | アザ複素環式化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9493444B2 (enExample) |
| EP (1) | EP2807154B1 (enExample) |
| JP (1) | JP2015505542A (enExample) |
| KR (1) | KR20140117641A (enExample) |
| CN (1) | CN104080773B (enExample) |
| AU (1) | AU2013212175B2 (enExample) |
| BR (1) | BR112014018341A8 (enExample) |
| CA (1) | CA2862698A1 (enExample) |
| HK (1) | HK1202543A1 (enExample) |
| IL (1) | IL233705A0 (enExample) |
| MX (1) | MX2014009133A (enExample) |
| RU (1) | RU2014134909A (enExample) |
| SG (1) | SG11201404217XA (enExample) |
| WO (1) | WO2013110433A1 (enExample) |
| ZA (1) | ZA201406322B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2696572C2 (ru) | 2012-03-07 | 2019-08-05 | Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) | 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение |
| EP3417851B1 (en) | 2013-09-09 | 2020-07-22 | Peloton Therapeutics, Inc. | Aryl ethers and uses thereof |
| CA2922469A1 (en) | 2013-09-11 | 2015-03-19 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| EP3722277A3 (en) * | 2013-10-04 | 2021-01-20 | Novartis AG | 3'end caps for rna-interferring agents for use in rna |
| CA2931085C (en) | 2013-12-16 | 2021-10-19 | Peloton Therapeutics, Inc. | Cyclic sulfone and sulfoximine analogs and uses thereof |
| GB201322333D0 (en) * | 2013-12-17 | 2014-01-29 | Agency Science Tech & Res | WNT pathway modulators |
| US10512626B2 (en) | 2015-03-11 | 2019-12-24 | Peloton Therapeautics, Inc. | Compositions for use in treating glioblastoma |
| EP3268362B1 (en) | 2015-03-11 | 2021-10-20 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
| US10807948B2 (en) | 2015-03-11 | 2020-10-20 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
| WO2016145032A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
| US10335388B2 (en) | 2015-04-17 | 2019-07-02 | Peloton Therapeutics, Inc. | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
| US9796697B2 (en) | 2015-06-12 | 2017-10-24 | Peloton Therapeutics, Inc. | Tricyclic inhibitors of HIF-2-alpha and uses thereof |
| WO2017062688A1 (en) | 2015-10-08 | 2017-04-13 | Suzhou Yunxuan Yiyao Keji Youxian Gongsi | Wnt signaling pathway inhibitors and therapeutic applications thereof |
| JP6853819B2 (ja) * | 2015-10-08 | 2021-03-31 | スーチョウ ユンシュアン イーヤオ カジ ヨウシェン ゴンス | Ｗｎｔシグナル伝達経路阻害剤およびその治療用途 |
| BR112020009361A2 (pt) | 2017-11-17 | 2020-10-13 | Cellix Bio Private Limited | composto de fórmula i, composição farmacêutica para tratar um distúrbio ocular ou complicações do mesmo, método de síntese de composto, método de tratamento de um distúrbio ocular ou complicações do mesmo em um indivíduo que precisa do mesmo e uso de um composto |
| JP7319395B2 (ja) * | 2019-06-14 | 2023-08-01 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１の阻害剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102105464A (zh) * | 2008-05-27 | 2011-06-22 | 德克萨斯大学系统董事会 | Wnt蛋白信号转导抑制剂 |
| GB0818241D0 (en) * | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
-
2013
- 2013-01-10 CN CN201380006903.4A patent/CN104080773B/zh not_active Expired - Fee Related
- 2013-01-10 SG SG11201404217XA patent/SG11201404217XA/en unknown
- 2013-01-10 KR KR1020147023947A patent/KR20140117641A/ko not_active Withdrawn
- 2013-01-10 EP EP13701200.1A patent/EP2807154B1/en not_active Not-in-force
- 2013-01-10 AU AU2013212175A patent/AU2013212175B2/en not_active Expired - Fee Related
- 2013-01-10 JP JP2014553655A patent/JP2015505542A/ja not_active Ceased
- 2013-01-10 WO PCT/EP2013/000050 patent/WO2013110433A1/en not_active Ceased
- 2013-01-10 CA CA2862698A patent/CA2862698A1/en not_active Abandoned
- 2013-01-10 MX MX2014009133A patent/MX2014009133A/es unknown
- 2013-01-10 BR BR112014018341A patent/BR112014018341A8/pt not_active IP Right Cessation
- 2013-01-10 HK HK15103108.6A patent/HK1202543A1/xx unknown
- 2013-01-10 RU RU2014134909A patent/RU2014134909A/ru unknown
- 2013-01-10 US US14/375,072 patent/US9493444B2/en not_active Expired - Fee Related
-
2014
- 2014-07-17 IL IL233705A patent/IL233705A0/en unknown
- 2014-08-27 ZA ZA2014/06322A patent/ZA201406322B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014134909A (ru) | Азагетероциклические соединения | |
| US20250223270A1 (en) | Sulfonamide Compounds and Use Thereof | |
| US11028088B2 (en) | Modulators of BTK proteolysis and methods of use | |
| US20200038513A1 (en) | Modulators of fak proteolysis and associated methods of use | |
| JP2024059874A (ja) | ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤 | |
| JP6736559B2 (ja) | トリアゾロピリミジン化合物およびその使用 | |
| KR101910720B1 (ko) | 키나제 억제제로서의 아미노헤테로아릴 벤즈아미드 | |
| JP6545199B2 (ja) | ３−アミノ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類 | |
| JP7738550B2 (ja) | Ｅｒｋ１およびｅｒｋ２の複素環式阻害剤の使用のための改善された方法、キット、組成物、ならびに投与レジメン | |
| AU2019249849A1 (en) | BRM targeting compounds and associated methods of use | |
| WO2018226542A1 (en) | Modulators of proteolysis and associated methods of use | |
| KR20210025061A (ko) | 세레블론(crbn)에 대한 리간드 | |
| JP2017532360A5 (enExample) | ||
| RS57177B1 (sr) | Derivati benzamida za inhibiranje aktivnosti abl1, abl2 i bcr-abl1 | |
| HRP20171655T1 (hr) | Derivati aminopirimidina za upotrebu kao modulatori aktivnosti kinaze | |
| MX2008008191A (es) | Combinacion de un inhibidor iap y un taxano 7. | |
| US20200121684A1 (en) | Modulators of btk proteolysis and methods of use | |
| US20220071970A1 (en) | Quinuclidine-3-one derivatives and their use in cancer treatment | |
| CA3063804A1 (en) | A class of isoindolone-imide ring-1,3-dione-2-ene compounds, composition and use thereof | |
| US20190202826A1 (en) | Phosphotidylinositol 3-Kinase Inhibitors | |
| JP2025509965A (ja) | がんを治療するための組成物及び方法 | |
| WO2020198067A1 (en) | Pkm2 modulators and methods for their use | |
| JP2011514339A5 (enExample) | ||
| HK1239664B (en) | Triazolopyrimidine compounds and uses thereof | |
| HK1239664A1 (en) | Triazolopyrimidine compounds and uses thereof |